The known timing of HIV infection in perinatal transmission, combined with the capacity for early antiretroviral therapy (ART) initiation and immune reconstitution, can provide unique insights into HIV persistence. The scientific basis for a pediatric-specific research agenda aimed at HIV remission and cure is discussed.
INTRODUCTION
With nearly 3.2 million children living with HIV and 260 000 new cases in 2014, it is imperative to continuously align the pediatric treatment agenda with that in adults. As in HIV-infected adults, antiretroviral therapy (ART) in HIV-infected infants and children significantly improves morbidity and mortality, as demonstrated by 75% decreases in the risks of disease progression and death [1] . The almost immediate establishment of HIV latency in a small pool of resting memory CD4 þ T cells, however, presents the major barrier to HIV clearance and cure [2] . This is because of the intrinsic, long-lived nature of the reservoir for HIV in resting memory CD4 þ T cells, which self-renew, promote viral quiescence in their resting state, and preclude targeting by antiretroviral drugs and immune surveillance mechanisms. The hope for remission in perinatal infection stems from the capacity to treat infection soon after birth given that the timing of HIV exposure is known, resulting in a favorable state for immunotherapeutic interventions aimed at HIV remission.
of anti-HIV drugs that can reverse HIV latency [latency reversing agents (LRA)] to promote the clearance of latent reservoirs toward HIV remission and cure, where HIV remission can be defined as a prolonged period of undetectable plasma viremia without ART [3] . A recent mathematical model showed that the size of the latent reservoir is important with respect to rebound times off ART based on the stochastic nature of reactivation [4 & ]. It is estimated that reducing the size of the reservoir from 1/ 10 6 to 1/10 8-9 may afford 1 year of HIV remission in which patients can discontinue ART without experiencing viremic relapse within the typical 2-3 weeks of stopping treatment [5, 6, 7 && ,8]. Several proof-of-concept studies have demonstrated that latent HIV in infected adults can indeed be induced to become transcriptionally active with LRAs [9-11], although this has not led to measureable reductions in latently infected cells [9, 10] .
One approach to reducing HIV reservoirs in infected individuals is through early treatment [ 
BIOMARKERS OF HIV PERSISTENCE
Perinatal HIV infection may occur in utero during the last trimester, peripartum, or postnatally through breastfeeding, all of which are preventable with the identification and treatment of pregnant women. Nevertheless, new infections in children provide an opportunity to systematically study the effects of very early and early treatment (defined as ART initiation within 2-3 days or 2-3 months of age, respectively) on reservoir reduction to enable virologic remission. In the case of the Mississippi Child, virologic rebound occurred after an unprecedented period of 27 months of virologic remission [19, 22] . The recurrence of viremia following a period of absent HIV-specific immune responses and circulating infected cells highlights the unpredictable nature of viremic rebound and the overt lack of biomarkers to detect persistent replication-competition HIV, and supports the notion of HIV dormancy. Although unfortunate for the individual child, rebound viremia provides hope that HIV can indeed be controlled for prolonged periods through latency.
Although the very early treatment of perinatal infection is not the standard of care, a clinical trial of this approach to perinatal infection is underway that should provide new knowledge on the effects of very early virologic control on the early restriction of HIV reservoirs and HIV remission [National Clinical Trial (NCT) #02140255; also known as the International Maternal Pediatric Adolescent AIDS Clinical Trials Network's P1115 study]. In a recent study [13 & ], treatment of HIV infection within 2-3 months of age did not immediately restrict reservoirs from forming, emphasizing the need for very early interventions to immediately influence HIV reservoirs in perinatal infection. In this study, a
KEY POINTS
The Mississippi Child, who maintained 27 months of virologic remission, and the French Adolescent, who has remained in remission for more than a decade, provide hope for HIV remission among perinatally HIV-infected infants, children, and adolescents.
The known timing of HIV infection in perinatal transmission, combined with the capacity for early treatment initiation and immune reconstitution, distinguishes perinatal infection from adult infection. These characteristics permit the evaluation of the effects and timing of interventions on changes in the size and composition of the latent HIV reservoir.
Early treatment remains the standard of care in perinatal HIV infection and generates a favorable viroimmunologic profile in which immunotherapeutic strategies can be evaluated.
Studies are under development to evaluate the effects of immunotherapeutics such as monoclonal bNAbs in the context of early ART initiation.
high concentration of transcriptionally active HIVinfected cells was established in perinatally infected infants by a median of 2 months of age. Although HIV-infected cells decreased significantly with 2 years of virologic suppression, proviral HIV DNA was detectable in 100% of 12 infants and HIV transcripts were detectable in 75% of eight infants. A significant correlation was observed between HIV DNA concentrations before and after ART, suggesting that the proviral DNA reservoir after 2 years of virologic suppression is determined by the size of the infected cell pool established before ART initiation. In another recent study of perinatally infected children treated early with ART [23 && ], time to virologic suppression and age at ART initiation was associated with size of the proviral DNA reservoir after at least 7 years of virologic suppression. Infants who initiated ART by 12 weeks of age had six-fold lower proviral DNA concentrations than those who initiated ART by 12-54 weeks of age. This strongly suggests that early treatment initiation results in small proviral reservoir size, possibly by skewing the seeding of short-lived cells and permitting continual decay of HIVinfected cells [23 && ]. Low proviral DNA concentrations do not ensure long-term remission, however, as perinatally infected children experience plasma viral rebound within days of ART discontinuation, irrespective of their proviral DNA load (reviewed in [24] ). Therefore, small proviral reservoir size may not result in permanent virologic remission, but it may provide an optimal platform for studies aimed at purging the reservoir with other immunotherapeutic interventions.
The reservoir is established in the context of immunologic memory, for which the developing infant immune system may be differentially affected than in adults (Table 1) . The nearly 15 years of experience with the early treatment of perinatal infection has led to the identification of unique virologic and immunologic features with durable suppression. Although smaller HIV reservoir size is strongly associated with early ART initiation, the composition of the reservoir is also affected by early treatment. HIV persistence during early effective therapy is of limited genetic diversity [37] . Over time, however, HIV persistence may be driven by the clonal expansion of infected cells. Studies of HIV-infected adults and children observed identical HIV sequences integrated in the same human genes across multiple cells [38, 39] , suggesting specific integration sites are associated with clonal expansion of HIV-infected cells. In early-treated, longterm suppressed perinatally infected children and adolescents, more than 99% of noninduced proviral genomes were replication-defective using molecular methods to probe cultured cells that did not yield replication-competent HIV via the traditional quantitative viral outgrowth assay [ 
IMMUNOTHERAPEUTIC INTERVENTIONS
The prevention of HIV-specific immune responses by early treatment initiation allows the development of uninhibited autologous immunity following HIV-specific vaccination, that can be measured without interference by autologous immunity and the use of monoclonal antibodies without de novo antibody-mediated viral escape mutations. Several HIV vaccines tested in HIV-exposed infants were well tolerated and immunogenic, as demonstrated by durable envelope (Env)-specific IgG responses that remained detectable through 2 years of age in 56% of recipients [40] . Anti-variable regions 1 and 2 (V1V2) IgG, identified in the RV144 vaccine trial in adults as a correlate of protection from HIV infection [41] , was also elicited in HIV-exposed infants receiving an ALVAC HIV vaccine series or the Novartis glycoprotein (gp)120 subunit protein vaccine, providing support for further trials of protein-only or single gene vaccines in perinatal infection [42] . Env-specific antibodies have the potential to neutralize HIV, a feature that may be particularly relevant in children rendered antibody seronegative from early treatment, and these antibodies are undergoing studies of very early treatment to achieve virologic remission. Goo et al. identified cross-clade neutralizing antibodies in 71% of 28 HIV-infected Kenyan infants, indicating that infants are also capable of developing HIV-specific neutralizing antibody responses despite their perceived 'immature' immune systems [43 [45] ). Typically, these antibodies develop several years after HIV infection and poorly neutralize the circulating virus of the individual from which the bNAb was isolated. bNAbs confer antiviral activity against HIV in murine [46, 47] and nonhuman primate [48] models by targeting the envelope protein and have exceptionally broad and potent neutralizing activity against a diverse panel of HIV variants [49] , including almost all HIV subtypes [50] . A recent study in adults showed that 44-72% of HIV latent reservoir clones were neutralized by the bNAbs VRC01 and PGT121 [41] , which have entered into phase 1 clinical trials in HIV-infected adults [51] (NCT #02411539, 02568215, 02471326, and 02463227) and infants (NCT #02256631). A recent study of untreated mother-infant pairs showed 50-78% neutralization of circulating HIV subtype B and G viruses with bNAbs, albeit in the setting of uncontrolled virus replication in the first year of life [52] . Whether bNAbs would prevent viremic relapse in early-treated perinatal infection will require study, but conceivably they could serve to neutralize HIV emerging from latency. Additionally, the duration of bNAb efficacy after administration is currently unclear, but will be particularly promising when long-acting preparations become available. There is extensive pediatric experience on the use of monoclonal antibodies to prevent or attenuate viral infections; most notably, Synagis is used for the prevention of respiratory syncytial virus infection in high-risk infants [53, 54] . Therefore, a monoclonal antibody approach will likely have acceptability in the HIV remission/cure space. Given that the reestablishment of viremia with ART cessation is likely derived from reactivated HIV from latent reservoirs, knowledge of the inhibitory profiles of bNAbs against latent perinatal HIV reservoir viruses is an important first step for assessing this strategy.
CONCLUSION
The inclusion of HIV-infected women and their newborns in clinical trials investigating novel approaches to HIV prevention and treatment is not without precedent. Despite the vulnerable nature of involving pregnant women and their newborn infants in clinical trials, important lessons were learnt from the first studies of antiretroviral drugs to prevent HIV transmission. These studies led to marked reductions in the risk of mother-to-child HIV transmission from as high as 30-40% without interventions to as low as 2% [55, 56] , making perinatal HIV a largely preventable disease. The landmark Pediatric AIDS Clinical Trials Group 076 clinical trial [55] highlights how knowledge of HIV exposure provided the optimal framework to study interventions toward shifting treatment paradigms for pregnant women and their infants, and transforming an epidemic. The HIV Prevention Trials Network 040/Pediatric AIDS Clinical Trials Group 1043 trial demonstrated that combination ART initiated within 48 h of birth decreased HIV transmission by 50% in nonbreastfed infants born to mothers who did not receive antenatal ART [56] , suggesting that more potent ART regimens may be effective during the eclipse phase of early infection. Thus, the perinatal HIV remission agenda should be considered for the unique components from which insights into HIV persistence can be gained. Without remission, perinatally infected individuals are destined to live with this infection for their entire lives. Issues such as ART adherence, toxicities, and drug resistance should further motivate this cause. Current efforts to scale up early infant diagnosis and treatment, including the development of rapid, point-of-care testing and immediate treatment of high-risk infants, should affect the significant morbidity and mortality associated with untreated HIV infection in infancy, while at the same time providing a platform for studies of HIV remission and cure.
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